Quarterly report pursuant to Section 13 or 15(d)

Mezzanine Equity

Mezzanine Equity
9 Months Ended
Sep. 30, 2023
Temporary Equity [Abstract]  
Mezzanine Equity Mezzanine Equity
Series S Preferred Stock
On December 28, 2022 the Company acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company’s Series S Convertible Preferred Stock. Shares of Series S Convertible Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. As of September 30, 2023 and December 31, 2022, there were 100,000 shares of Series S Convertible Preferred Stock outstanding.